Department of Radiology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Québec, Canada.
Department of Urology, Centre Hospitalier Universitaire de Québec, Quebec, Québec, Canada.
Can Assoc Radiol J. 2014 Aug;65(3):253-9. doi: 10.1016/j.carj.2013.08.001. Epub 2013 Dec 7.
The objective of this study was to evaluate the diagnostic performance of ultrasound for detecting urinary tract neoplasm in the setting of macroscopic hematuria by using multidetector computed tomography urography (MDCTU) and cystoscopy as the reference standard.
This retrospective study was approved by our institutional review board. Patients with macroscopic hematuria who were investigated with an abdominal or renal ultrasound, an MDCTU, and a cystoscopy between January 2007 and December 2009, were eligible (95 patients). Exclusion criteria were time interval >12 months between index and reference tests or the absence of histopathologic proof of malignancy. Ultrasound results of the remaining 86 patients were collected and compared with the reference standard test, which was the combination of MDCTU for the assessment of upper urinary tract and cystoscopy for assessment of the lower urinary tract. The final diagnosis of neoplasm was based on pathologic findings.
Urinary tract neoplasm was diagnosed in 20% of the patients (17/86). Sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios of ultrasound for detecting urinary tract neoplasms were 35.3% (6/17), 89.9% (62/69), 46.2% (6/13), 84.9% (62/73), 3.48 (95% confidence interval, 1.34-9.02), and 0.72 (95% confidence interval, 0.5-1.3), respectively.
Sensitivity of ultrasound for the evaluation of macroscopic hematuria in the era of MDCTU is lower than expected. Results of our study suggest that patients with macroscopic hematuria should undergo MDCTU as first-line imaging modality, with little added benefit from ultrasound.
本研究旨在通过多排螺旋 CT 尿路造影(MDCTU)和膀胱镜检查作为参考标准,评估超声检查在肉眼血尿患者中诊断尿路肿瘤的性能。
本回顾性研究获得了我院伦理委员会的批准。2007 年 1 月至 2009 年 12 月期间,因肉眼血尿接受腹部或肾脏超声、MDCTU 和膀胱镜检查的患者符合入选条件(95 例)。排除标准为指数和参考检验之间的时间间隔>12 个月或缺乏恶性肿瘤的组织病理学证据。收集并比较了其余 86 例患者的超声结果与参考标准测试,参考标准测试包括 MDCTU 用于评估上尿路和膀胱镜检查用于评估下尿路。肿瘤的最终诊断基于病理结果。
17/86(20%)患者诊断为尿路肿瘤。超声检查检测尿路肿瘤的敏感性、特异性、阳性预测值、阴性预测值、阳性似然比和阴性似然比分别为 35.3%(6/17)、89.9%(62/69)、46.2%(6/13)、84.9%(62/73)、3.48(95%置信区间,1.34-9.02)和 0.72(95%置信区间,0.5-1.3)。
在 MDCTU 时代,超声检查评估肉眼血尿的敏感性低于预期。我们的研究结果表明,对于肉眼血尿患者,应将 MDCTU 作为一线成像方式,超声检查的获益不大。